AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEWLY DIAGNOSED CANCERS
This research is looking at a new treatment called IGM-8444 for different types of cancer, including bowel cancer. It's a very early study, called a Phase 1a/1b trial, which means researchers are mainly checking if the new medicine is safe for people and what dose works best. They also want to understand how the medicine affects the body when given by itself or with other standard cancer treatments. The study is for adults who have cancer that has either returned after previous treatment, hasn't improved with other treatments, or has been diagnosed recently and hasn't yet been treated. This is an important step to see if IGM-8444 could be a helpful new option for cancer patients in the future.
At a glance
What is this study about?
This study is focused on a new potential cancer treatment called IGM-8444. Researchers are carefully exploring this medicine in people, including those with bowel cancer. It's called a 'Phase 1a/1b study,' which means it's one of the very first times this medicine is being given to humans. The main goals at this stage are to understand if it's safe, what side effects it might cause, and to find the right amount (dose) of the medicine to give.
The study will look at how IGM-8444 works when given by itself, and also when it's combined with other existing cancer treatments. This helps scientists see if it could be an effective standalone treatment or if it works better alongside other medicines to fight cancer. The study involves people whose cancer has either come back after previous treatment, hasn't responded to their current treatments, or has been newly diagnosed.
By taking part in studies like this, volunteers help doctors learn more about new medicines. This research is a crucial step in the long process of developing new and better ways to treat cancer, potentially offering new hope for patients in the future. It's important to remember that because this is an early-stage study, the primary focus is on safety and understanding the drug, rather than already knowing if it will cure cancer.
Key takeaways
- This is an early study of a new cancer medicine, IGM-8444.
- It aims to check safety and find the right dose for various cancers, including bowel cancer.
- It's for people whose cancer has returned, not responded to other treatments, or is newly diagnosed.
- Participation helps future cancer treatments.
- Regular clinic visits and tests will be needed.
- You can stop participating at any time.
Who may be eligible?
To be considered for this study, you must be 18 years old or older – there's no upper age limit. The study is open to everyone, regardless of whether you are male or female.
Specifically, this study is for adults who have been diagnosed with certain types of cancer, including bowel cancer. This includes people whose cancer has come back after treatment, those whose cancer hasn't responded to previous treatments, or individuals who have just been diagnosed with cancer and are looking for treatment options.
There will be other detailed health requirements that the study team will discuss with you. These are put in place to ensure your safety and to make sure the study results are as clear as possible. A doctor or nurse involved in the study will review your medical history to see if this study is right for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of cancer, including bowel cancer?
- Has your cancer come back, not responded to treatment, or is it newly diagnosed?
- Are you able to attend regular clinic appointments?
- Are you open to discussing your full medical history with the study team?
What does participation involve?
If you decide to take part in this study, you would first have a full health check-up to make sure it's safe for you. You would then receive the study medicine, IGM-8444, which might be given alone or alongside other standard cancer treatments, depending on which part of the study you are in. The medicine will likely be given over a period of time, and you'll need to visit the clinic regularly. These visits will involve blood tests, physical examinations, and possibly scans to monitor your health and how the medicine is affecting your cancer.
Throughout the study, the research team will keep a close eye on you to check for any side effects and to see how your body is responding to the treatment. The total length of your participation can vary, but these early-stage studies often involve regular visits over several months, followed by a period of follow-up for your health. You'll be given a clear schedule of appointments and what to expect at each one.
Potential risks and benefits
Locations (2)
- —UnverifiedSpain
- —UnverifiedFrance
Common questions
What is IGM-8444?
IGM-8444 is a new medicine being tested as a potential treatment for certain cancers, including bowel cancer.
What does 'Phase 1a/1b study' mean?
It means this is a very early study in people, focusing on checking if the medicine is safe and finding the right dose, rather than curing cancer at this stage.
Who can join this study?
Adults aged 18 or over with certain types of cancer, including bowel cancer, whose cancer has returned, hasn't improved with other treatments, or is newly diagnosed.
Will I get better if I join the study?
Because this is an early study, we don't know yet if the medicine will help your cancer. The main goal is to understand safety and dose.
Can I stop participating if I want to?
Yes, you can leave the study at any time, for any reason, and it won't affect your ongoing medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.